Skip to main content

What Amgen's Quarter ended Sep 30, 2026 10-Q says: 3 signals

Amgen filed its latest 10-Q with the SEC on Nov 3, 2026. It discusses bookings decline, compliance burden and pricing pressure.

Public (AMGN)Biotechnology Research10,000+ employeesamgen.comLinkedIn

Get Amgen's live signals in Claude or ChatGPT, or by API

AskWhat changed at Amgen this week? Use Autobound signals for amgen.com.
Filed
Nov 3, 2026
Period
Quarter ended Sep 30, 2026
Filings
3
Signals
12

Source: Autobound Signal API · 83 signals tracked for Amgen · updated

10-Q · latest 10

What Amgen's 10-Q filings say

  1. 10-Q · Quarter ended Sep 30, 2026

    Filed · 3 signals

    SEC EDGAR
  2. 10-Q · Quarter ended Jun 30, 2026

    Filed · 4 signals

    SEC EDGAR
  3. 10-Q · Quarter ended Mar 31, 2026

    Filed · 5 signals

    SEC EDGAR

Showing 10 of 12 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Amgen earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
New Chief Financial Officer appointed to lead capital allocationThomas J. Dittrich joined Amgen as Chief Financial Officer, marking his first quarterly earnings call with the company in this role. Dittrich outlined key priorities focusing on operational efficiency, disciplined capital allocation, and driving durable long-term growth. New leadership often initiates comprehensive vendor and operational strategy reviews.
Deploying artificial intelligence across drug discovery and manufacturing operationsAmgen is implementing artificial intelligence and data-driven insights across enterprise operations to accelerate speed and operational efficiency. The digital initiative spans early drug discovery, clinical development, manufacturing processes, and global product delivery. This creates engagement opportunities for vendors of enterprise AI, life sciences data platforms, and advanced analytics...
Scaling specialized field operations team for bispecific clinical deliveryAmgen has scaled a dedicated field organization termed the bispecific operations team to support clinical adoption and patient safety monitoring. Originally created for hematology and lung cancer drugs, the team is now expanding to support genitourinary oncology practices with outpatient implementation. This commercial model evolution requires healthcare workflow and patient-monitoring support...
Non-GAAP R&D spending increased 11% year-over-yearResearch and development spending grew 11% year-over-year in the third quarter. The increase in spend was driven by investments in research and the early-stage pipeline, alongside business development activities.
Tepezza revenue dropped 6% due to prior-year inventory buildTEPEZZA generated $526 million in sales during Q3, representing a 6% year-over-year decline attributed to comparisons against a significant customer inventory build in the prior year. Despite international launches across more than 20 countries, domestic inventory normalization created a headwind. This dynamic highlights supply-chain visibility and demand-forecasting software needs.
SG&A expenses decreased 1% through targeted ongoing productivity effortsAmgen reduced non-GAAP SG&A expenses by 1% year-over-year in the third quarter, driven in part by ongoing enterprise productivity efforts and the timing of investments. Operating margins reached 47% non-GAAP in Q3, with full-year margin guidance targeting 45% to 46% of product sales. Operational efficiency remains a top agenda item under the new financial leadership.

Signal API · MCP

Track Amgen with the Signal API

One POST /v1/companies/enrich call with amgen.com returns Amgen 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"amgen.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about Amgen 10-Q

When did Amgen file its latest 10-Q?
Amgen filed its latest 10-Q (Quarter ended Sep 30, 2026) on Nov 3, 2026. The one before it was filed on Aug 4, 2026.
What did Amgen disclose in its latest 10-Q?
From the filing dated Nov 3, 2026: ENBREL net selling price fell 19% in nine months from IRA Medicare price setting
What did Amgen say on its recent earnings calls?
Q3 FY2026: New Chief Financial Officer appointed to lead capital allocation (dated Nov 3, 2026).
Where can I read Amgen's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/amgn-20260930.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →